Regeneron Pharmaceuticals (REGN) Share-based Compensation (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Share-based Compensation of $243.0 million for Q2 2026, down 3.46% year-over-year from $251.7 million in Q2 2025, and down 5.59% quarter-over-quarter from $257.4 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Share-based Compensation (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Share-based Compensation history runs 18 years deep, the most recent figure standing at $243.0 million for Q2 2026.
- In Q2 2026, Share-based Compensation fell 3.46% year-over-year to $243.0 million; the TTM figure through Jun 2026 stood at $986.7 million (up 12.0% YoY), while the FY2025 annual figure was $993.7 million, down 3.44% from the prior year.
- Share-based Compensation for Q2 2026 stood at $243.0 million, down from $257.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $343.7 million in Q1 2024, with the low at $120.2 million in Q3 2024.
- The 5-year median for Share-based Compensation is $239.6 million (2023), against an average of $229.6 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation slumped 60.16% in 2022, then jumped 97.17% in 2025.
- Regeneron Pharmaceuticals' Share-based Compensation stood at $232.0 million in 2022, then advanced by 3.62% to $240.4 million in 2023, then gained by 5.41% to $253.4 million in 2024, then dropped by 1.62% to $249.3 million in 2025, then dropped by 2.53% to $243.0 million in 2026.
- Business Quant data shows REGN's Share-based Compensation at $243.0 million in Q2 2026, $257.4 million in Q1 2026, and $249.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 83.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 243.00 Mn |
| Jun 30, 2026 | 243.00 Mn |
| Mar 31, 2026 | 257.40 Mn |
| Mar 31, 2026 | 257.40 Mn |
| Dec 31, 2025 | -212.30 Mn |
| Dec 31, 2025 | -212.30 Mn |
| Sep 30, 2025 | 237.00 Mn |
| Sep 30, 2025 | 237.00 Mn |
| Jun 30, 2025 | 503.10 Mn |
| Jun 30, 2025 | 503.10 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Dec 31, 2024 | 304.40 Mn |
| Dec 31, 2024 | 304.40 Mn |
| Sep 30, 2024 | 22.90 Mn |
| Sep 30, 2024 | 22.90 Mn |
| Jun 30, 2024 | 311.80 Mn |
| Jun 30, 2024 | 311.80 Mn |
| Mar 31, 2024 | 343.70 Mn |
| Mar 31, 2024 | 343.70 Mn |